SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001720725-22-000032
Filing Date
2022-03-18
Accepted
2022-03-18 16:46:59
Documents
14
Period of Report
2022-03-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oyst-20220314.htm   iXBRL 8-K 38442
2 EX-99.1 exhibit991-pressrelease.htm EX-99.1 16622
6 image_0.jpg GRAPHIC 268869
  Complete submission text file 0001720725-22-000032.txt   543526

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT oyst-20220314.xsd EX-101.SCH 1917
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT oyst-20220314_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT oyst-20220314_pre.xml EX-101.PRE 13053
8 EXTRACTED XBRL INSTANCE DOCUMENT oyst-20220314_htm.xml XML 11265
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39112 | Film No.: 22753123
SIC: 2836 Biological Products, (No Diagnostic Substances)